Papers - TANAKA Hisashi
-
Prognostic impact of oligometastasis in older patients with extensive-stage small cell lung cancer.
Morinaga D, Hashimoto K, Asahina H, Tanaka H, Honjo O, Harada T, Yokouchi H, Kikuchi H, Shigaki R, Takashina T, Nakamura K, Kawai Y, Takahashi M, Kida R, Sukoh N, Ito K, Takahashi A, Hommura H, Ohhara Y, Furuta M, Konno S, Hosomi Y, Oizumi S.
Respir Investig. 17 ( 63 ) 373 - 382 2025.3
-
Skin disorder within 30 days is a favorable prognostic factor in patients with lung squamous cell carcinoma treated with necitumumab plus gemcitabine and cisplatin: a sub-analysis of the NINJA study.
Kinoshita F, Tanzawa S, Misumi T, Yoshioka H, Miyauchi E, Ninomiya K, Murata Y, Takeshita M, Yamaguchi M, Sugawara S, Kawashima Y, Hashimoto K, Mori M, Miyanaga A, Hayashi A, Tanaka H, Honda R, Nojiri M, Sato Y, Yamamoto K, Masuda K, Kozuki T, Kawamura T, Suzuki T, Yamaguchi T, Asada K, Tetsumoto S, Tanaka H, Watanabe S, Umeda Y, Yamaguchi K, Kuyama S, Tsuruno K, Misumi Y, Kuraishi H, Yoshihara K, Nakao A, Kubo A, Yokoyama T, Watanabe K, Seki N.
Ther Adv Med Oncol. 2025.3
-
Exploration of clinical Biomarkers for guiding treatment selection between chemotherapy and combination therapy with Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in EGFR-Mutant NSCLC patients after EGFR-TKI Therapy: The SPIRAL-STEP study.
Morimoto K, Yamada T, Furuya N, Tanaka H, Yoshimura A, Oba T, Hibino M, Fukuda T, Goto Y, Nakao A, Ogusu S, Okazaki Y, Harada T, Ota T, Masubuchi K, Mikami K, Hata T, Matsumoto S, Honda R, Date K, Chihara Y, Takayama K.
Lung Cancer 2025.3
-
Clinical impact of hypomagnesemia induced by necitumumab plus cisplatin and gemcitabine treatment in patients with advanced lung squamous cell carcinoma: a subanalysis of the NINJA study.
Tanzawa S, Yoshioka H, Misumi T, Miyauchi E, Ninomiya K, Murata Y, Takeshita M, Kinoshita F, Fujishita T, Sugawara S, Kawashima Y, Hashimoto K, Mori M, Miyanaga A, Hayashi A, Tanaka H, Honda R, Nojiri M, Sato Y, Hata A, Ishikawa N, Kozuki T, Kawamura T, Saito G, Yamaguchi T, Asada K, Tetsumoto S, Tanaka H, Watanabe S, Umeda Y, Yamaguchi K, Nishii K, Tsuruno K, Misumi Y, Kuraishi H, Yoshihara K, Nakao A, Kubo A, Yokoyama T, Watanabe K, Seki N.
Ther Adv Med Oncol. 2025.2
-
Long-term outcome of chemoimmunotherapy for extensive-stage small-cell lung cancer according to key clinical trial eligibility: 3-year outcomes from a prospective cohort study.
Sugisaka J, Fujimoto D, Tamiya M, Hata A, Matsumoto H, Yokoyama T, Taniguchi Y, Uchida J, Sato Y, Kijima T, Tanaka H, Furuya N, Masuda T, Sakata Y, Miyauchi E, Saito G, Miura S, Yamaguchi T, Daga H, Sakata S, Yamamoto N, Akamatsu H.
Lung Cancer. 2025.1
-
Identification of key gene signatures for predicting chemo-immunotherapy efficacy in extensive-stage small-cell lung cancer using machine learning.
Fujimoto D, Shibaki R, Kimura K, Haratani K, Tamiya M, Kijima T, Sato Y, Hata A, Yokoyama T, Taniguchi Y, Uchida J, Tanaka H, Furuya N, Miura S, Onishi MI, Sakata S, Miyauchi E, Yamamoto N, Koh Y, Akamatsu H.
Lung Cancer. 2025.1
-
Impact of Cachexia and First-Line Systemic Therapy for Previously Untreated Advanced Non-Small Cell Lung Cancer: NEJ050A.
Miura K, Shukuya T, Furuya N, Morita R, Kisohara A, Mouri A, Watanabe S, Tanaka H, Hirata A, Hakozaki T, Hamai K, Matsumoto N, Watanabe K, Ashinuma H, Miyauchi E, Sugano K, Hosokawa S, Amano K, Morita S, Kobayashi K, Maemonodo M, Takahashi K.
J Cachexia Sarcopenia Muscle. 2024.12
-
Comparison of immune checkpoint inhibitor plus chemotherapy or ipilimumab plus nivolumab-based therapy for NSCLC patients with PD-L1 TPS (1-49 %): TOPGAN2023-01.
Tanaka H, Makiguchi T, Tozuka T, Kawashima Y, Oba T, Tsugitomi R, Koyama J, Tambo Y, Ogusu S, Saiki M, Gyotoku H, Hasegawa T, Miyauchi E, Sonoda T, Saito R, Nakatomi K, Sakatani T, Kudo K, Tsuchiya-Kawano Y, Nishio M.
Eur J Cancer. 2024.12
-
Durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non-small-cell lung cancer (NEJ056).
Furuta M, Horinouchi H, Yokota I, Yamaguchi T, Itoh S, Fukui T, Iwashima A, Sugisaka J, Miura Y, Tanaka H, Miyawaki T, Yokouchi H, Miura K, Saito R, Saito G, Kamoshida T, Uchinami Y, Kato T, Kobayashi K, Asahina H.
Cancer Sci. 2024.11
-
Highly sensitive and accurate detection of ALK-TKI resistance mutations by oligoribonucleotide interference-PCR (ORNi-PCR)-based methods.
Tabe C, Fujita T, Taima K, Tanaka H, Makiguchi T, Itoga M, Ishioka Y, Tasaka S, Fujii H.
Lung Cancer. 197 2024.11
-
Non-small cell lung cancer with synchronous brain metastases: Identification of prognostic factors in a retrospective multicenter study (HOT 1701).
Ohhara Y, Kojima T, Honjo O, Yamada N, Sato T, Takahashi H, Takamura K, Takashina T, Sukoh N, Tanaka H, Kawai Y, Fujita Y, Yokoo K, Hommura F, Harada T, Honda R, Amano T, Dosaka-Akita H, Oizumi S, Kinoshita I.
Neurooncol Adv. 2024.10
-
Real-world first-line treatment with pembrolizumab for non-small cell lung carcinoma with high PD-L1 expression: Updated analysis.
Ikezawa Y, Morita R, Mizugaki H, Tateishi K, Yokoo K, Sumi T, Kikuchi H, Kitamura Y, Nakamura A, Kobayashi M, Aso M, Kimura N, Yoshiike F, Megumi F, Tanaka H, Sekikawa M, Hachiya T, Nakamura K, Hommura F, Sukoh N, Ito K, Kikuchi T, Agatsuma T, Yokouchi H.
Cancer Med. 13 ( 14 ) 2024.7
-
Endocrine immune-related adverse event is a prognostic biomarker independent of lead-time bias.
Ishidoya M, Makiguchi T, Tanaka H, Miura T, Nunomura Y, Miura D, Morimoto T, Hasegawa Y, Taima K, Tasaka S
Lung cancer (Amsterdam, Netherlands) 192 107790 2024.6
-
Durvalumab after chemoradiotherapy in non-small cell lung cancer with EGFR mutation: A real-world study (HOT2101).
Tsuji K, Mizugaki H, Yokoo K, Kobayashi M, Kawashima Y, Kimura N, Yokouchi H, Kikuchi H, Sumi T, Kawai Y, Kobashi K, Morita R, Ito K, Kitamura Y, Minemura H, Nakamura K, Aso M, Honjo O, Tanaka H, Takashina T, Tsurumi K, Sugisaka J, Tsukita Y, Konno S, Oizumi S.
Cancer Sci. 115 ( 4 ) 1273 - 1282 2024.4
-
Machine learning analysis of pathological images to predict 1-year progression-free survival of immunotherapy in patients with small-cell lung cancer.
Shibaki R, Fujimoto D, Nozawa T, Sano A, Kitamura Y, Fukuoka J, Sato Y, Kijima T, Matsumoto H, Yokoyama T, Miura S, Hata A, Tamiya M, Taniguchi Y, Sugisaka J, Furuya N, Tanaka H, Yamamoto N, Koh Y, Akamatsu H.
J Immunother Cancer 2024.2
-
Machine learning analysis of pathological images to predict 1-year progression-free survival of immunotherapy in patients with small-cell lung cancer.
Shibaki R, Fujimoto D, Nozawa T, Sano A, Kitamura Y, Fukuoka J, Sato Y, Kijima T, Matsumoto H, Yokoyama T, Miura S, Hata A, Tamiya M, Taniguchi Y, Sugisaka J, Furuya N, Tanaka H, Yamamoto N, Koh Y, Akamatsu H.
J Immunother Cancer. 2024.2
-
Role of G-protein-coupled estrogen receptor in the pathogenesis of chronic asthma.
Itoga M, Ishioka Y, Makiguchi T, Tanaka H, Taima K, Saito N, Tomita H, Tasaka S.
Immunol Lett 2024.2
-
Durvalumab after chemoradiotherapy in non-small cell lung cancer with EGFR mutation: A real-world study (HOT2101)
Tsuji K, Mizugaki H, Yokoo K, Kobayashi M, Kawashima Y, Kimura N, Yokouchi H, Kikuchi H, Sumi T, Kawai Y, Kobashi K, Morita R, Ito K, Kitamura Y, Minemura H, Nakamura K, Aso M, Honjo O, Tanaka H, Takashina T, Tsurumi K, Sugisaka J, Tsukita Y, Konno S, Oizumi S.
Cancer Sci. 2024.1
-
Extended ICI treatment after first-line chemoimmunotherapy could predict the clinical benefit of ramucirumab plus docetaxel in advanced non-small lung cancer: Post hoc analysis from NEJ051 (REACTIVE study).
Yamaguchi O, Mori K, Takata S, Shibata K, Chikamori K, Kimura N, Nagai Y, Nakagawa T, Igawa S, Harada T, Yoshioka H, Tanaka H, Nogawa H, Satoh H, Shiozawa T, Tsuji K, Kobayashi K, Kaira K.
Thorac Cancer. 2024.1
-
A phase II study of atezolizumab with bevacizumab, carboplatin, and paclitaxel for patients with EGFR-mutated NSCLC after TKI treatment failure (NEJ043 study).
Watanabe S, Furuya N, Nakamura A, Shiihara J, Nakachi I, Tanaka H, Nakao M, Minato K, Seike M, Sasaki S, Kisohara A, Takeuchi S, Honda R, Takamura K, Kagamu H, Yoshimura K, Kobayashi K, Kikuchi T.
Eur J Cancer. 2024.1
-
A phase II study of atezolizumab with bevacizumab, carboplatin, and paclitaxel for patients with EGFR-mutated NSCLC after TKI treatment failure (NEJ043 study).
Watanabe S, Furuya N, Nakamura A, Shiihara J, Nakachi I, Tanaka H, Nakao M, Minato K, Seike M, Sasaki S, Kisohara A, Takeuchi S, Honda R, Takamura K, Kagamu H, Yoshimura K, Kobayashi K, Kikuchi T.
Eur J Cancer. 2024.1
-
Extended ICI treatment after first-line chemoimmunotherapy could predict the clinical benefit of ramucirumab plus docetaxel in advanced non-small lung cancer: Post hoc analysis from NEJ051 (REACTIVE study).
Yamaguchi O, Mori K, Takata S, Shibata K, Chikamori K, Kimura N, Nagai Y, Nakagawa T, Igawa S, Harada T, Yoshioka H, Tanaka H, Nogawa H, Satoh H, Shiozawa T, Tsuji K, Kobayashi K, Kaira K.
Thorac Cancer. 2023.11
-
Multicenter, Retrospective Study to Evaluate Necitumumab Plus Cisplatin and Gemcitabine After Immune Checkpoint Inhibitors in Advanced Squamous Cell Lung Cancer in Japan: The NINJA Study.
Okamoto T, Sugawara S, Kawashima Y, Hashimoto K, Mori M, Miyanaga A, Hayashi A, Tanaka H, Honda R, Nojiri M, Sato Y, Hata A, Masuda K, Kozuki T, Kawamura T, Suzuki T, Yamaguchi T, Asada K, Tetsumoto S, Tanaka H, Watanabe S, Umeda Y, Yamaguchi K, Kuyama S, Tsuruno K, Misumi Y, Kuraishi H, Yoshihara K, Nakao A, Kubo A, Yokoyama T, Watanabe K, Seki N.
JTO Clin Res Rep 2023.10
-
Subsequent treatment for locally advanced non-small-cell lung cancer that progressed after definitive chemoradiotherapy and consolidation therapy with durvalumab: a multicenter retrospective analysis (TOPGAN 2021-02).
Hasegawa T, Ariyasu R, Tanaka H, Saito R, Kawashima Y, Horiike A, Sakatani T, Tozuka T, Shiihara J, Saiki M, Tambo, Sonoda T, Miya
Cancer Chemother Pharmacol 2023.7
-
Prospective exosome-focused translational research for afatinib (EXTRA) study of patients with nonsmall cell lung cancer harboring EGFR mutation: an observational clinical study.
Takata S, Morikawa K, Tanaka H, Itani H, Ishihara M, Horiuchi K, Kato Y, Ikemura S, Nakagawa H, Nakahara Y, Seki Y, Bessho A, Takahashi N, Hayashi K, Endo T, Takeyama K, Maekura T, Takigawa N, Kawase A, Endoh M, Nemoto K, Kishi K, Soejima K, Okuma Y, Yoshimura K, Saigusa D, Kanai Y, Ueda K, Togashi A, Matsutani N, Seki N.
Ther Adv Med Oncol 2023.6
-
Hokkaido Lung Cancer Clinical Study Group Trial. Real-world data on the efficacy and safety of immune-checkpoint inhibitors in elderly patients with non-small cell lung cancer.
Morinaga D, Asahina H, Ito S, Honjo O, Tanaka H, Honda R, Yokouchi H, Nakamura K, Takamura K, Hommura F, Kawai Y, Ito K, Sukoh N, Yokoo K, Morita R, Harada T, Takashina T, Goda T, Dosaka-Akita H, Isobe H
Cancer Med. 2023.5
-
Safety and feasibility of carboplatin and paclitaxel in combination with nintedanib for non-small cell lung cancer patients with idiopathic pulmonary fibrosis: A prospective pilot study.
Makiguchi T, Tanaka H, Okudera K, Taima K, Tasaka S.
Transl Lung Cancer Res. 2023.4
-
Granulomatosis with Polyangiitis following COVID-19 in an Adolescent.
Nakamura Y, Okumura F, Nihei M, Chubachi K, Sakamoto H, Ishioka Y, Makiguchi T, Tanaka H, Taima K, Yajima N, Kurose A, Tasaka S.
Intern Med. 62 ( 4 ) 589 - 593 2023.2
-
Granulomatosis with Polyangiitis following COVID-19 in an Adolescent.
Nakamura Y, Okumura F, Nihei M, Chubachi K, Sakamoto H, Ishioka Y, Makiguchi T, Tanaka H, Taima K, Yajima N, Kurose A, Tasaka S.
Intern Med. 2023.2
-
Outcomes of Chemoimmunotherapy Among Patients With Extensive-Stage Small Cell Lung Cancer According to Potential Clinical Trial Eligibility
Fujimoto D, Morimoto T, Tamiya M, Hata A, Matsumoto H, Nakamura A, Yokoyama T, Taniguchi Y, Uchida J, Sato Y, Yokoi T, Tanaka H, Furuya N, Masuda T, Sakata Y, Miyauchi E, Hara S, Saito G, Miura S, Kanazu M, Yamamoto N, Akamatsu H.
JAMA Netw Open 6 ( 2 ) 2023.2
-
Clinical efficacy of amrubicin in patients with small cell lung cancer relapse after first-line treatment including immune checkpoint inhibitors: A retrospective multicenter study (TOPGAN 2021-01)
Uematsu S, Kitazono S, Tanaka H, Saito R, Kawashima Y, Ohyanagi F, Tozuka T, Ryosuke T, Sakatani T, Horiike A, Yoshizawa T, Saiki M, Tambo Y, Koyama J, Kanazu M, Kudo K, Tsuchiya-Kawano Y, Yanagitani N, Nishio M.
Thorac Cancer. 14 ( 2 ) 2023.1
-
A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study): primary analysis.
Tanaka H, Tanzawa S, Misumi T, Makiguchi T, Inaba M, Honda T, Nakamura J, Inoue K, Kishikawa T, Nakashima M, Fujiwara K, Kohyama T, Ishida H, Kuyama S, Miyazawa N, Nakamura T, Miyawaki H, Oda N, Ishikawa N, Morinaga R, Kusaka K, Fujimoto N, Fukuda Y, Yasugi M, Tsuda T, Ushijima S, Shibata K, Shibayama T, Bessho A, Kaira K, Shiraishi K, Matsutani N, Seki N.
Ther Adv Med Oncol. 14 2022.12
-
Acute Exacerbation of Interstitial Lung Disease After SARS-CoV-2 Vaccination: A Case Series.
Ishioka Y, Makiguchi T, Itoga M, Tanaka H, Taima K, Goto S, Tasaka S
Chest 162 ( 6 ) e311 - e316 2022.12
-
A randomized comparison of nivolumab versus nivolumab + docetaxel for previously treated advanced or recurrent ICI-naïve non-small-cell lung cancer: TORG1630
28 ( 20 ) 4402 - 4409 2022.10
-
クライオバイオプシーで診断した肺クリプトコックス症の1例．
小田切 遥, 牧口 友紀, 福島 高志, 石岡 佳子, 糸賀 正道, 田中 寿志, 當麻 景章, 田坂 定智．
気管支学（日本呼吸器内視鏡学会雑誌) 44 ( 5 ) 325 - 330 2022.9
-
Feasibility and safety of platinum-doublet therapy in patients with small-cell lung cancer in the third-line setting: A multi-institutional retrospective study.
Fukushima T, Makiguchi T, Tanaka Y, Chubachi K, Ishidoya M, Suzuki S, Tanaka H, Taima K, Hasegawa Y, Okudera K, Tasaka S.
Oncol Lett. 24 ( 4 ) 368 2022.9
-
HER2遺伝子変異陽性肺癌に対して化学放射線療法後にデュルバルマブを投与した1例．
佐々木悠子，田中寿志，牧口友紀，小堀由璃，小田切遥，田坂定智．
日本呼吸器学会誌 11(5) 310 - 314 2022.9
-
Morphological features of bronchiectasis in patients with non-tuberculous mycobacteriosis and interstitial pneumonia.
Tabe C, Dobashi M, Ishioka Y, Itoga M, Tanaka H, Taima K, Tasaka S.
BMC Res Notes 15 263 2022.7
-
Current status of first-line treatment with pembrolizumab for non-small-cell lung cancer with high PD-L1 expression.
Ikezawa Y, Mizugaki H, Morita R, Tateishi K, Yokoo K, Sumi T, Kikuchi H, Kitamura Y, Nakamura A, Kobayashi M, Aso M, Kimura N, Yoshiike F, Furuta M, Tanaka H, Sekikawa M, Hachiya T, Nakamura K, Shimokawa M, Oizumi S.
2022.6
-
Clinical efficacy of dacomitinib in rechallenge setting for patients with epidermal growth factor receptor mutant non-small cell lung cancer: A multicenter retrospective analysis (TOPGAN2020-02).
Tanaka H, Sakamoto H, Akita T, Ohyanagi F, Kawashima Y, Tambo Y, Tanimoto A, Horiike A, Miyauchi E, Tsuchiya-Kawano Y, Yanagitani N, Nishio M.
Thorac Cancer. 2022.5
-
Diabetic ketoacidosis shortly after COVID-19 vaccination in a non–small-cell lung cancer patient receiving combination of PD-1 and CTLA-4 inhibitors: A case report.
Makiguchi T, Tanaka H, Taima K, Takayasu S, Tasaka S
Thorac Cancer 13 ( 8 ) 1220 - 1223 2022.4
-
Diabetic ketoacidosis shortly after COVID-19 vaccination in a non–small-cell lung cancer patient receiving combination of PD-1 and CTLA-4 inhibitors: A case report
2022.2
-
Bilateral Thalamic Lesions Associated With Atezolizumab-Induced Encephalitis: A Follow-up Report With Autopsy Findings.
Nishijima H, Kon T, Seino Y, Yagihashi N, Suzuki C, Nakamura T, Tanaka H, Sakamoto Y, Wakabayashi K, Tomiyama M
Neurology 98 ( 5 ) 204 - 205 2022.2
-
Clinical Significance of Tumor Markers for Advanced Thymic Carcinoma: A Retrospective Analysis from the NEJ023 Study.
Tomoyasu Mimori, Takehito Shukuya, Ryo Ko, Yusuke Okuma, Tomonobu Koizumi, Hisao Imai, Yuichi Takiguchi, Eisaku Miyauchi, Hiroshi Kagamu, Tomohide Sugiyama, Keisuke Azuma, Yukiko Namba, Masahiro Yamasaki, Hisashi Tanaka, Yuta Takashima, Sayo Soda, Osamu Ishimoto, Nobuyuki Koyama, Kunihiko Kobayashi, Kazuhisa Takahashi
Cancers 14 ( 2 ) 2022.1
-
Clinical Significance of Tumor Markers for Advanced Thymic Carcinoma: A Retrospective Analysis from the NEJ023 Study
Mimori T, Shukuya T, Ko , Okuma Y, Koizumi T, Imai H, Takiguchi Y, Miyauchi E, Kagamu H, Sugiyama T, Azuma K, Namba Y, Yamasaki M, Tanaka H, Takashima Y, Soda S, Ishimoto O, Koyama N, Kobayashi K, Takahashi K
Cancers (Basel) 2022.1
-
肺癌診療ガイドライン
田中寿志
肺癌診療ガイドライン2022年度版 2022
-
Ⅲ各種抗がん薬 22-17. MET阻害薬
田中寿志
新臨床腫瘍学（改訂第7版） 2022
-
First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002).
Gaku Yamamoto, Hajime Asahina, Osamu Honjo, Toshiyuki Sumi, Atsushi Nakamura, Kenichiro Ito, Hajime Kikuchi, Fumihiro Hommura, Ryoichi Honda, Keiki Yokoo, Yuka Fujita, Satoshi Oizumi, Ryo Morita, Yasuyuki Ikezawa, Hisashi Tanaka, Nozomu Kimura, Takaaki Sasaki, Noriaki Sukoh, Taichi Takashina, Toshiyuki Harada, Hirotoshi Dosaka-Akita, Hiroshi Isobe
Scientific reports 11 ( 1 ) 23140 - 23140 2021.11
-
Immune-mediated thrombocytopenia induced with durvalumab after chemoradiotherapy in a non-small cell lung cancer patient: A case report.
Makiguchi T, Tanaka H, Kamata K, Taima K, Kurose A, Tasaka S
Thoracic cancer 12 ( 20 ) 2811 - 2814 2021.10
-
Immune-mediated thrombocytopenia induced with durvalumab after chemoradiotherapy in a non-small cell lung cancer patient: A case report.
Tomonori Makiguchi, Hisashi Tanaka, Kosuke Kamata, Kageaki Taima, Akira Kurose, Sadatomo Tasaka
Thoracic cancer 12 ( 20 ) 2811 - 2814 2021.8
-
The relationship between evolving sarcopenia and efficacy of immune checkpoint inhibitor in non-small cell lung cancer patients
2021.7
-
The relationship between evolving sarcopenia and efficacy of immune checkpoint inhibitor in non-small cell lung cancer patients.
Makiguchi T, Tanaka H, Taima K, Tatsuo S, Iida S, Kakeda S, Tasaka S.
JCSM Clin Rep 2021.7
-
The relationship between evolving sarcopenia and efficacy of immune checkpoint inhibitor in non-small cell lung cancer patients.
Makiguchi T, Tanaka H, Taima K, Tatsuo S, Iida S, Kakeda S, Tasaka S
JCSM Clinical Reports 6 103 - 108 2021.7
-
Randomized phase 2 study comparing irinotecan versus amrubicin as maintenance therapy after first-line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401).
Hisashi Tanaka, Yukihiro Hasegawa, Yuka Fujita, Atsushi Nakamura, Eiki Kikuchi, Yasutaka Kawai, Toshiyuki Harada, Naomi Watanabe, Hiroshi Yokouchi, Kazuhiro Usui, Ryota Saito, Hiroshi Watanabe, Tomomi Masuda, Tatsuro Fukuhara, Keita Kudo, Ryoichi Honda, Satoshi Oizimi, Makoto Maemondo, Akira Inoue, Naoto Morikawa
Thoracic cancer 12 ( 14 ) 2113 - 2121 2021.6
-
Prognostic factors in patients with advanced non-small cell lung cancer after long-term Anti-PD-1 therapy (HOT1902).
Shotaro Ito, Hajime Asahina, Osamu Honjo, Hisashi Tanaka, Ryoichi Honda, Satoshi Oizumi, Keiichi Nakamura, Kei Takamura, Fumihiro Hommura, Yasutaka Kawai, Kenichiro Ito, Noriaki Sukoh, Keiki Yokoo, Ryo Morita, Toshiyuki Harada, Taichi Takashina, Tomohiro Goda, Hirotoshi Dosaka-Akita, Hiroshi Isobe
Lung cancer (Amsterdam, Netherlands) 156 12 - 19 2021.6
-
Procalcitonin expression in patients with large cell neuroendocrine carcinoma of the lung.
Masamichi Itoga, Hisashi Tanaka, Kageaki Taima, Yoshiko Ishioka, Hiroaki Sakamoto, Shingo Takanashi, Akira Kurose, Sadatomo Tasaka
BMC research notes 14 ( 1 ) 25 - 25 2021.1
-
Activity and bioavailability of tepotinib for leptomeningeal metastasis of NSCLC with MET exon 14 skipping mutation.
Hisashi Tanaka, Kageaki Taima, Tomonori Makiguchi, Junichi Nakagawa, Takenori Niioka, Sadatomo Tasaka
Cancer communications (London, England) 41 ( 1 ) 83 - 87 2021.1
-
Activity and bioavailability of tepotinib for leptomeningeal metastasis of NSCLC with MET exon 14 skipping mutation.
Hisashi Tanaka, Kageaki Taima, Tomonori Makiguchi, Junichi Nakagawa, Takenori Niioka, Sadatomo Tasaka
Cancer communications (London, England) 41 ( 1 ) 83 - 87 2021.1
-
The efficacy of nintedanib in 158 patients with idiopathic pulmonary fibrosis in real-world settings: A multicenter retrospective study.
Masaki Dobashi, Hisashi Tanaka, Kageaki Taima, Masamichi Itoga, Yoshiko Ishioka, Toshihiro Shiratori, Fumihiko Okumura, Chiori Tabe, Yoshihito Tanaka, Takeshi Morimoto, Yukihiro Hasegawa, Hideo Yasugahira, Koichi Okudera, Shingo Takanashi, Sadatomo Tasaka
SAGE open medicine 9 20503121211023357 - 20503121211023357 2021
-
日本臨床 領域別症候群シリーズ 腫瘍性疾患 「Pancoast症候群」
田中 寿志、田坂 定智
肺癌診療ガイドライン 2021年度版 2021
-
A Phase I/II study of biweekly carboplatin and nab-paclitaxel with concurrent radiotherapy for patients with locally advanced unresectable stage III non-small cell lung cancer.
Tanaka H, Hasegawa Y, Makiguchi T, Okumura F, Tabe C, Shiratori T, Ishioka Y, Itoga M, Taima K, Yokouchi J, Hatayama Y, Aoki M, Tasaka S.
Clin Lung Cancer 22(1) 42 - 48 2021
-
Hypothesis generative head-to-head study comparing efficacy of afatinib and osimertinib based on immunological biomarkers in Japanese NSCLC patients with EGFR mutations (Heat on Beat study).
Kei Morikawa, Hisashi Tanaka, Hidetoshi Itani, Saori Takata, Satoshi Watanabe, Kazuma Kishi, Kenzo Soejima, Kyoichi Kaira, Hiroshi Kagamu, Kenichi Yoshimura, Noriyuki Matsutani, Nobuhiko Seki
Therapeutic advances in medical oncology 12 1758835920967254 - 1758835920967254 2020.10
-
Phase II Study of Low-Dose Afatinib Maintenance Treatment Among Patients with EGFR-Mutated Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1601 (NJLCG1601).
Atsushi Nakamura, Hisashi Tanaka, Ryota Saito, Aya Suzuki, Toshiyuki Harada, Sumito Inoue, Toru Yamada, Taku Nakagawa, Daisuke Jingu, Shunichi Sugawara
The oncologist 25 ( 10 ) e1451 - e1456 2020.10
-
A Phase I/II Study of Biweekly Carboplatin and Nab-paclitaxel With Concurrent Radiotherapy for Patients With Locally Advanced Unresectable Stage III Non-small-cell Lung Cancer.
Hisashi Tanaka, Yukihiro Hasegawa, Tomonori Makiguchi, Fumihiko Okumura, Chiori Tabe, Toshihiro Shiratori, Yoshiko Ishioka, Masamichi Itoga, Kageaki Taima, Junichi Yokouchi, Yoshiomi Hatayama, Masahiko Aoki, Sadatomo Tasaka
Clinical lung cancer 22 ( 1 ) 42 - 48 2020.10
-
A Phase I/II Study of Biweekly Carboplatin and Nab-paclitaxel With Concurrent Radiotherapy for Patients With Locally Advanced Unresectable Stage III Non-small-cell Lung Cancer.
Hisashi Tanaka, Yukihiro Hasegawa, Tomonori Makiguchi, Fumihiko Okumura, Chiori Tabe, Toshihiro Shiratori, Yoshiko Ishioka, Masamichi Itoga, Kageaki Taima, Junichi Yokouchi, Yoshiomi Hatayama, Masahiko Aoki, Sadatomo Tasaka
Clinical lung cancer 22 ( 1 ) 42 - 48 2020.10
-
Effect of nintedanib on non-small cell lung cancer in a patient with idiopathic pulmonary fibrosis: A case report and literature review.
Toshihiro Shiratori, Hisashi Tanaka, Chiori Tabe, Junichiro Tsuchiya, Yoshiko Ishioka, Masamichi Itoga, Kageaki Taima, Shingo Takanashi, Sadatomo Tasaka
Thoracic cancer 11 ( 6 ) 1720 - 1723 2020.6
-
Destroyed lung due to sustained inflammation after chemoradiotherapy followed by durvalumab.
Kageaki Taima, Hisashi Tanaka, Masamichi Itoga, Yoshiko Ishioka, Akira Kurose, Sadatomo Tasaka
Respirology case reports 8 ( 5 ) e00580 - e00580 2020.5
-
A pilot study of adjuvant chemotherapy with carboplatin and oral S-1 for patients with completely resected stage II to IIIA non-small cell lung cancer
Tanaka H, Tabe C, Okumura F, Shiratori T, Ishioka Y, Itoga M, Taima K, Morimoto T, Kimura D, Tsushima T, Tasaka S.
Thorac Cancer 11 1633 - 1638 2020.4
-
Factors Influencing Decision-making in Relation to the Administration of Durvalumab After Chemoradiotherapy (TOPGAN2020-01)
Ariyasu Ryo, Tambo Yuichi, Tanimoto Azusa, Sonoda Tomoaki, Koyama Junji, Uenami Takeshi, Kudo Keita, Tsuchiya Yuko, Nishio Makoto, Uchibori Ken, Tanaka Hisashi, Miyauchi Eisaku, Kawashima Yosuke, Ohyanagi Fumiyoshi, Horiike Atsushi, Sakatani Toshio, Saiki Masafumi
Haigan 60 ( 7 ) 966 - 971 2020
-
The efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer harboring driver mutations.
Hiroaki Sakamoto, Hisashi Tanaka, Toshihiro Shiratori, Keisuke Baba, Yoshiko Ishioka, Masamichi Itoga, Kageaki Taima, Yukihiro Hasegawa, Shingo Takanashi, Sadatomo Tasaka
Molecular and clinical oncology 10 ( 6 ) 610 - 614 2019.6
-
Real-world study of afatinib in first-line or re-challenge settings for patients with EGFR mutant non-small cell lung cancer.
Hisashi Tanaka, Kageaki Taima, Masamichi Itoga, Yoshiko Ishioka, Keisuke Baba, Toshihiro Shiratori, Hiroaki Sakamoto, Junichiro Tsuchiya, Hideyuki Nakagawa, Yukihiro Hasegawa, Hideo Yasugahira, Koichi Okudera, Shingo Takanashi, Sadatomo Tasaka
Medical oncology (Northwood, London, England) 36 ( 6 ) 57 - 57 2019.5
-
Prospective exosome-focused translational research for afatinib study of non-small cell lung cancer patients expressing EGFR (EXTRA study).
Yusuke Okuma, Kei Morikawa, Hisashi Tanaka, Takuma Yokoyama, Hidetoshi Itani, Kazuya Horiuchi, Hideyuki Nakagawa, Nobumasa Takahashi, Akihiro Bessho, Kenzo Soejima, Kazuma Kishi, Akira Togashi, Yae Kanai, Koji Ueda, Katsuhisa Horimoto, Noriyuki Matsutani, Nobuhiko Seki
Thoracic cancer 10 ( 2 ) 395 - 400 2019.2
-
Efficacy of pembrolizumab for patients with both high PD-L1 expression and an MET exon 14 skipping mutation: A case report.
Keisuke Baba, Hisashi Tanaka, Hiroaki Sakamoto, Toshihiro Shiratori, Junichiro Tsuchiya, Yoshiko Ishioka, Masamichi Itoga, Kageaki Taima, Sadatomo Tasaka
Thoracic cancer 10 ( 2 ) 369 - 372 2019.2
-
Efficacy of pembrolizumab for patients with both high PD-L1 expression and an MET exon 14 skipping mutation: A case report.
Baba K, Tanaka H, Sakamoto H, Shiratori T, Tsuchiya J, Ishioka Y, Itoga M, Taima K, Tasaka S
Thorac Cancer 2019.1
-
Prognostic Factors and Efficacy of First-Line Chemotherapy in Patients with Advanced Thymic Carcinoma: A Retrospective Analysis of 286 Patients from NEJ023 Study.
Ryo Ko, Takehito Shukuya, Yusuke Okuma, Kazunari Tateishi, Hisao Imai, Shunichiro Iwasawa, Eisaku Miyauchi, Akiko Fujiwara, Tomohide Sugiyama, Keisuke Azuma, Keiko Muraki, Masahiro Yamasaki, Hisashi Tanaka, Yuta Takashima, Sayo Soda, Osamu Ishimoto, Nobuyuki Koyama, Satoshi Morita, Kunihiko Kobayashi, Toshihiro Nukiwa, Kazuhisa Takahashi,
The oncologist 23 ( 10 ) 1210 - 1217 2018.10
-
脊髄炎，感覚性軸索型ニューロパチーを呈した傍腫瘍性神経症候群の1例
土屋純一郎，田中 寿志，當麻 景章 他
日本呼吸器学会誌 7 ( 4 ) 212 - 215 2018.7
-
A phase I study of afatinib for patients aged 75 or older with advanced non-small cell lung cancer harboring EGFR mutations.
Hisashi Tanaka, Kageaki Taima, Yoshihito Tanaka, Masamichi Itoga, Yoshiko Ishioka, Hideyuki Nakagawa, Keisuke Baba, Yukihiro Hasegawa, Shingo Takanashi, Sadatomo Tasaka
Medical oncology (Northwood, London, England) 35 ( 3 ) 34 - 34 2018.2
-
A single-arm phase II study of nab-paclitaxel for patients with chemorefractory non-small cell lung cancer.
Hisashi Tanaka, Kageaki Taima, Takeshi Morimoto, Yoshihito Tanaka, Masamichi Itoga, Kunihiko Nakamura, Akihito Hayashi, Mika Kumagai, Hideo Yasugahira, Megumi Mikuniya, Koichi Okudera, Shingo Takanashi, Sadatomo Tasaka
BMC cancer 17 ( 1 ) 683 - 683 2017.10
-
Dramatic response to alectinib in a patient of ALK-rearranged lung cancer with poor performance status.
Hisashi Tanaka, Kageaki Taima, Takeshi Morimoto, Kunihiko Nakamura, Yoshihito Tanaka, Masamichi Itoga, Shingo Takanashi, Ken Okumura
BMC research notes 9 ( 1 ) 173 - 173 2016.3
-
Plasma homocysteine levels and hematological toxicity in NSCLC patients after the first cycle of pemetrexed under folate supplementation.
Hisashi Tanaka, Atsushi Horiike, Toshio Sakatani, Ryota Saito, Noriko Yanagitani, Keita Kudo, Fumiyoshi Ohyanagi, Takeshi Horai, Makoto Nishio
Anti-cancer drugs 26 ( 5 ) 573 - 578 2015.6
-
Sepsis caused by Listeria monocytogenes during chemotherapy for small cell carcinoma of the thymus.
Masamichi Itoga, Yuko Asari, Takeshi Morimoto, Kageaki Taima, Kunihiko Nakamura, Yoshihito Tanaka, Hisashi Tanaka, Shingo Takanashi, Hiroyuki Kayaba, Ken Okumura
BMC research notes 8 268 - 268 2015.6
-
Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer.
Atsushi Horiike, Nobuyuki Yamamoto, Hisashi Tanaka, Noriko Yanagitani, Keita Kudo, Fumiyoshi Ohyanagi, Akira Ono, Tateaki Naito, Haruyasu Murakami, Takeshi Horai, Makoto Nishio
Anticancer research 34 ( 4 ) 1975 - 1981 2014.4
-
The long-term survival of a thymic carcinoma patient treated with S-1: a case report and literature review.
Hisashi Tanaka, Takeshi Morimoto, Kageaki Taima, Yoshihito Tanaka, Kunihiko Nakamura, Akihito Hayashi, Akira Kurose, Ken Okumura, Shingo Takanashi
OncoTargets and therapy 7 87 - 90 2013.12
-
Clinical application of immunocytochemical detection of ALK rearrangement on cytology slides for detection or screening of lung adenocarcinoma.
Hisashi Tanaka, Kiyoshi Tone, Akihito Hayashi, Takeshi Morimoto, Kageaki Taima, Yoshihito Tanaka, Hideyuki Nakagawa, Shingo Takanashi, Ken Okumura, Akira Kurose
Lung cancer (Amsterdam, Netherlands) 80 ( 3 ) 289 - 292 2013.6
-
A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALK fusion gene.
Hisashi Tanaka, Akihito Hayashi, Takeshi Morimoto, Kageaki Taima, Yoshihito Tanaka, Michiko Shimada, Akira Kurose, Shingo Takanashi, Ken Okumura
BMC cancer 12 558 - 558 2012.11